Starting with the best: Novavax shares are up more than 2,400% this year. The Maryland-based company's vaccine candidate, NVX‑CoV2373, is in the latter half of its phase 1/2 clinical trial. The company released encouraging phase 1 results on Aug. 4, with the vaccine causing no severe adverse side effects. Read More...
Up Over 300% Since the March Crash, Are These 3 Big Names Still Good Buys Today?
Starting with the best: Novavax shares are up more than 2,400% this year. The Maryland-based company’s vaccine candidate, NVX‑CoV2373, is in the latter half of its phase 1/2 clinical trial. The company released encouraging phase 1 results on Aug. 4, with the vaccine causing no severe adverse side effects.
